logo
  

GEO Group Increases 2022 Financial Guidance

The GEO Group, Inc. (GEO) has increased its financial guidance for the full year 2022 and has issued guidance for the third and fourth quarters of 2022. The company expects full year 2022 annual revenues of approximately $2.35 billion. Adjusted net income is projected to be in a range of $1.28 to $1.34 per share. Full year AFFO is estimated to be in a range of $2.40 to $2.46 per share.

For the third quarter, the company expects quarterly revenues of $603 million to $608 million. AFFO is expected to be between $0.55 and $0.57 per share.

For the fourth quarter, the company expects quarterly revenues of $600 million to $605 million. AFFO is estimated to be between $0.52 and $0.56 per share.

Excluding items, GEO Group reported second quarter adjusted earnings of $50.97 million or $0.42 per share. Analysts on average had expected the company to earn $0.31 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items. Bottom line totaled $53.73 million, or $0.37 per share compared with $41.96 million, or $0.29 per share, prior year. Revenue rose 4.0% to $588.18 million from $565.42 million last year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hormel Foods Corp. (HRL) said, in the fourth quarter, the company delivered earnings per share comparable with record results last year, which included an additional week of sales. Pretax earnings were $357 million, up 1% from a year ago. Organic net sales were up 2%, excluding the impact of an additional... Over the Thanksgiving holiday weekend, from Thanksgiving Day to Cyber Monday, around 196.7 million Americans shopped in stores and online, higher than the previous year, according to the National Retail Federation or NRF. Black Friday continued to be the most favored day for in-store as well as online shopping during the five-day holiday period. Lenoir, North Carolina -based Exela Pharma Sciences, LLC has expanded its recall of Sodium Bicarbonate Injection due to vial breakage to include more lots, the U.S. Food and Drug Administration said. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton.
RELATED NEWS
Follow RTT